Novavax, Inc. (NASDAQ: NVAX) struggles to reach its 50-day simple moving average despite facing numerous obstacles in the market. On November 30, 2023, the company experienced a decrease of -1.08% in stock price, starting the day at $5.50. Throughout the day, the stock saw fluctuations, reaching a high of $5.705 and a low of $5.415 before closing at $5.56. Looking at a broader timeframe, NVAX has seen a 52-week range of $5.30 to $18.55.
Over the past five years, Novavax, Inc. has shown impressive annual sales growth of 525.36% in the healthcare sector. Its earnings per share (EPS) during this period reached 7.76%. However, the stock’s EPS for this year stands at 56.61%. With 118.79 million shares outstanding and a float of 110.21 million shares, the company’s market capitalization currently sits at $653.35 million. The 50-day moving average of NVAX is $6.59, while the 200-day moving average is $7.52.
Let’s delve into the actions of large-scale investors in the Biotechnology Industry regarding Novavax, Inc. The company’s current insider ownership accounts for 7.23%, while institutional ownership stands at 52.95%. In recent insider trades, the President of R&D purchased 1,000 shares at a rate of $6.50 on March 10, with a total transaction value of $6,500. This acquisition affected insider ownership by 14,473. Additionally, on March 07, the President of R&D bought 2,000 shares at $7.04, with a total transaction value of $14,088. Their total holdings now amount to 13,473 shares.
In the latest quarterly report released on September 29, 2023, Novavax, Inc. reported earnings per share (EPS) of -$1.26 for the three months, surpassing the consensus estimate of -$1.83 by $0.57. Market experts predict that the company will achieve earnings of -0.34 per share in the next fiscal year.
Novavax, Inc. has seen a notable increase of 56.61% in EPS for this current 12-month fiscal period and is projected to reach -0.80 in the upcoming year.
Examining the current performance indicators for NVAX, the company’s quick ratio in the last reported quarter stood at 0.64. The stock has achieved an average true range (ATR) of 0.38. Another important indicator to consider is the price-to-sales ratio for the trailing twelve months, currently at 0.62.
Furthermore, NVAX’s diluted earnings per share (EPS) for the trailing twelve months is recorded at -6.38. Analysts predict that this figure will reach 0.16 in the next quarter and -0.80 at the market close one year from now.
Considering the recent performance of Novavax, Inc., the average volume for the last five days was 5.36 million, a decrease compared to the year-to-date volume of 7.23 million. The company’s stochastic %D for the previous nine days was recorded at 32.59%, while the average true range (ATR) was 0.35.
Novavax, Inc.’s raw stochastic average for the previous 100 days is 4.00%, indicating a significant decline compared to the 14.39% during the last two weeks. In terms of volatility, the stock’s historic volatility in the past 14 days was 51.99%, lower than the 74.78% exhibited in the previous 100 days.
In summary, Novavax, Inc. finds itself -16.97% away from its 50-day simple moving average despite facing various challenges. The company has shown exceptional annual sales growth in the healthcare sector over the past five years. Major investors have made significant insider trades, impacting the company’s ownership. Novavax, Inc. has also exceeded earnings per share expectations in its latest quarterly report. As the market moves forward, analysts predict a positive outlook for the company’s EPS. However, the stock’s volatility and performance indicators require careful consideration.
